<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2552">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04397237</url>
  </required_header>
  <id_info>
    <org_study_id>2020-A01371-38</org_study_id>
    <nct_id>NCT04397237</nct_id>
  </id_info>
  <brief_title>Prevalence and Seroconversion of COVID-19 in Autoimmune Diseases in Europe</brief_title>
  <acronym>Euro-COVIMID</acronym>
  <official_title>Prevalence, Seroconversion and Impact of COVID-19 in Autoimmune Diseases in Europe</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pitié-Salpêtrière Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Groupe d'Études et de Recherche de l'Appareil Locomoteur (GERPAL)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Università degli Studi di Ferrara</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rheumazentrum Ruhrgebiet</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University College, London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Coimbra</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universidad Complutense de Madrid</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Pitié-Salpêtrière Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The coronavirus disease 2019 (COVID-19) pandemic is a potentially fatal disease that
      represents a great global public health concern. In European countries such as Spain, Italy,
      Germany, Portugal, England and France, the pandemic has been of utmost importance. To date,
      no treatment has been robustly validated, and two theoretically opposite therapeutic
      strategies are proposed, based either on antiretroviral therapy or on immunomodulating
      agents.

      In this complex context, people living with immune-mediated inflammatory diseases (IMID)
      raise specific concerns due to their potentially increased risk of infections or of severe
      infections. Among IMID, Sjögren's syndrome, systemic lupus erythematosus, rheumatoid
      arthritis, spondyloarthritis and giant cell arteritis are some key diseases.

      In this cross-sectional, observational, multi-centric study, the investigators aim to assess
      both clinical and serological prevalence of COVID-19 among samples of IMID patients in
      Europe. In parallel, the investigators aim to compare the prevalence of COVID-19
      seroconversion across these five IMIDs, their penetration across different 6 European
      countries (France, Italy, Spain, Germany, United Kingdom and Portugal), and to assess the
      severity of COVID-19 in these patients. Moreover, changes in treatment will be assessed,
      including immunomodulatory tapering or discontinuation, its causes over the outbreak period,
      as well as the incidence of IMID flares and their severity over this same period. Finally,
      patient's perceptions towards the pandemic will be evaluated and compared to medication
      beliefs.

      Data will be collected through questionnaires during medical visit or phone consultation and
      serological tests will be performed within routine blood collection. As so, all study
      procedures are comprised within usual care. Through this study the investigators expect to
      have a better knowledge of the clinical and serological prevalence of COVID-19 in IMID across
      Europe, along with the psychological, clinical, and therapeutic impact of COVID-19 in this
      particular patient population.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2020</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>COVID-19 seroconversion</measure>
    <time_frame>1 day, during routine blood collection</time_frame>
    <description>ELISA tests for COVID-19 antibodies</description>
  </primary_outcome>
  <primary_outcome>
    <measure>COVID-19 infection</measure>
    <time_frame>During medical visit or phone consultation, up to 2 hours</time_frame>
    <description>Case report form filled by the health professional</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Seroconversion rate by disease</measure>
    <time_frame>1 day, during routine blood collection</time_frame>
    <description>Descriptive analysis for each disease's rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Penetration across Europe</measure>
    <time_frame>1 day, during routine blood collection</time_frame>
    <description>Descriptive analysis for each country's rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>COVID-19 severity</measure>
    <time_frame>During medical visit, up to 1 hour</time_frame>
    <description>World Health Organization ordinal scale for clinical improvement at any given point of the infection, going from 0 to 8, where higher scores means worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>COVID-19 mortality rate</measure>
    <time_frame>During contact with family members, up to 1 hour</time_frame>
    <description>Descriptive analysis for overall and COVID-19-linked mortality rates</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>COVID-19 impact on immunomodulatory treatment</measure>
    <time_frame>During medical visit, up to 1 hour</time_frame>
    <description>Case report form filled by the health professional</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-reported flares</measure>
    <time_frame>During medical visit, up to 1 hour</time_frame>
    <description>Case report form filled by the patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's fears towards COVID-19</measure>
    <time_frame>During medical visit, up to 1 hour</time_frame>
    <description>Fear of COVID-19 scale, going from 7 to 35, where higher scores means worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's beliefs in their medicines towards COVID-19</measure>
    <time_frame>During medical visit, up to 1 hour</time_frame>
    <description>Beliefs about Medicines Questionnaire, going from 11 to 55, with higher scores indicating stronger beliefs regarding medicine.</description>
  </secondary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Anticipated">3600</enrollment>
  <condition>COVID-19</condition>
  <condition>Systemic Lupus Erythematosus</condition>
  <condition>Sjogren's Syndrome</condition>
  <condition>Axial Spondyloarthritis</condition>
  <condition>Rheumatoid Arthritis</condition>
  <condition>Giant Cell Arteritis</condition>
  <arm_group>
    <arm_group_label>Systemic Lupus Erythematosus</arm_group_label>
    <description>Consecutive Systemic Lupus Erythematosus patients followed-up in each service</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sjogren's Syndrome</arm_group_label>
    <description>Consecutive Sjogren's Syndrome patients followed-up in each service</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Axial Spondyloarthritis</arm_group_label>
    <description>Consecutive Axial Spondyloarthritis patients followed-up in each service</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rheumatoid Arthritis</arm_group_label>
    <description>Consecutive Rheumatoid Arthritis patients followed-up in each service</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Giant Cell Arteritis</arm_group_label>
    <description>Consecutive Giant Cell Arteritis patients followed-up in each service</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients followed-up for Sjögren's syndrome, systemic lupus erythematosus, rheumatoid
        arthritis, spondyloarthritis and giant cell arteritis in selected European tertiary-care
        centres will be contacted. The required number of patients with definite IMIDs who satisfy
        the inclusion criteria, followed-up in outpatient visits in the participating centres by
        one of the investigators, will be asked to participate. Consecutive patients fitting
        inclusion criteria will be selected in each centre in order to reduce bias selection.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years;

          -  Patients fitting classification criteria for each IMID (i.e., Sjögren's syndrome,
             systemic lupus erythematosus, rheumatoid arthritis, axial spondyloarthritis or giant
             cell arteritis);

          -  Willingness to participate;

          -  There are no specific inclusion criteria based on IMID previous activity, treatment or
             known COVID-19.

        Exclusion Criteria:

          -  Patients who refuse to participate;

          -  Patients who don't speak or read the local language,

          -  Patients unable to perform a routine blood collection during the study period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Saadoun, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pitié-Salpêtrière Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David Saadoun, MD, PhD</last_name>
    <phone>+33 1 42 17 80 42</phone>
    <email>david.saadoun@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Laure Gossec, MD, PhD</last_name>
    <phone>+33 1 42 17 84 21</phone>
    <email>laure.gossec@gmail.com</email>
  </overall_contact_backup>
  <link>
    <url>https://www.who.int/blueprint/priority-diseases/key-action/COVID-19_Treatment_Trial_Design_Master_Protocol_synopsis_Final_18022020.pdf</url>
    <description>World Health Organization Ordinal Scale for Clinical Improvement</description>
  </link>
  <link>
    <url>https://www.tandfonline.com/doi/abs/10.1080/08870449908407311</url>
    <description>Beliefs about Medicines Questionnaire</description>
  </link>
  <reference>
    <citation>Pope JE. What Does the COVID-19 Pandemic Mean for Rheumatology Patients? Curr Treatm Opt Rheumatol. 2020 Apr 30:1-4. doi: 10.1007/s40674-020-00145-y. [Epub ahead of print] Review.</citation>
    <PMID>32355607</PMID>
  </reference>
  <reference>
    <citation>Favalli EG, Agape E, Caporali R. Incidence and Clinical Course of COVID-19 in Patients with Connective Tissue Diseases: A Descriptive Observational Analysis. J Rheumatol. 2020 Aug 1;47(8):1296. doi: 10.3899/jrheum.200507. Epub 2020 Apr 25.</citation>
    <PMID>32335513</PMID>
  </reference>
  <reference>
    <citation>Mathian A, Mahevas M, Rohmer J, Roumier M, Cohen-Aubart F, Amador-Borrero B, Barrelet A, Chauvet C, Chazal T, Delahousse M, Devaux M, Euvrard R, Fadlallah J, Florens N, Haroche J, Hié M, Juillard L, Lhote R, Maillet T, Richard-Colmant G, Palluy JB, Pha M, Perard L, Remy P, Rivière E, Sène D, Sève P, Morélot-Panzini C, Viallard JF, Virot JS, Benameur N, Zahr N, Yssel H, Godeau B, Amoura Z. Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine. Ann Rheum Dis. 2020 Jun;79(6):837-839. doi: 10.1136/annrheumdis-2020-217566. Epub 2020 Apr 24.</citation>
    <PMID>32332072</PMID>
  </reference>
  <reference>
    <citation>Monti S, Balduzzi S, Delvino P, Bellis E, Quadrelli VS, Montecucco C. Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies. Ann Rheum Dis. 2020 May;79(5):667-668. doi: 10.1136/annrheumdis-2020-217424. Epub 2020 Apr 2.</citation>
    <PMID>32241793</PMID>
  </reference>
  <reference>
    <citation>Gianfrancesco MA, Hyrich KL, Gossec L, Strangfeld A, Carmona L, Mateus EF, Sufka P, Grainger R, Wallace Z, Bhana S, Sirotich E, Liew J, Hausmann JS, Costello W, Robinson P, Machado PM, Yazdany J; COVID-19 Global Rheumatology Alliance Steering Committee. Rheumatic disease and COVID-19: initial data from the COVID-19 Global Rheumatology Alliance provider registries. Lancet Rheumatol. 2020 May;2(5):e250-e253. doi: 10.1016/S2665-9913(20)30095-3. Epub 2020 Apr 16.</citation>
    <PMID>32309814</PMID>
  </reference>
  <reference>
    <citation>Ahorsu DK, Lin CY, Imani V, Saffari M, Griffiths MD, Pakpour AH. The Fear of COVID-19 Scale: Development and Initial Validation. Int J Ment Health Addict. 2020 Mar 27:1-9. doi: 10.1007/s11469-020-00270-8. [Epub ahead of print]</citation>
    <PMID>32226353</PMID>
  </reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 19, 2020</study_first_submitted>
  <study_first_submitted_qc>May 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 21, 2020</study_first_posted>
  <last_update_submitted>May 20, 2020</last_update_submitted>
  <last_update_submitted_qc>May 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Pitié-Salpêtrière Hospital</investigator_affiliation>
    <investigator_full_name>Pr David Saadoun</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>Systemic Lupus Erythematosus</keyword>
  <keyword>Sjogren's Syndrome</keyword>
  <keyword>Axial Spondyloarthritis</keyword>
  <keyword>Rheumatoid Arthritis</keyword>
  <keyword>Giant Cell Arteritis</keyword>
  <keyword>Prevalence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Sjogren's Syndrome</mesh_term>
    <mesh_term>Spondylarthritis</mesh_term>
    <mesh_term>Polymyalgia Rheumatica</mesh_term>
    <mesh_term>Giant Cell Arteritis</mesh_term>
    <mesh_term>Arteritis</mesh_term>
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
    <mesh_term>Autoimmune Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

